Heilongjiang Linbao Pharmaceutical Co., Ltd

Primary study objectives: Changes in blood Hcy compared to baseline at the end of the 16th week of treatment. Secondary study objectives: (1) Changes in blood Hcy compared to baseline at the end of the 2nd, 4th, and 8th week of treatment; (2) Blood Hcy values at the end of the 2nd, 4th, 8th, and 16th week of treatment; (3) Effectiveness at the end of the 2nd, 4th, 8th, and 16th week of treatment. (4) Changes in clinical symptoms at the end of the 2nd, 4th, 8th, and 16th week of treatment compared to baseline (Visit 1).

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of aspirin enteric-coated tablets (specification: 100 mg, applicant: Heilongjiang Linbao Pharmaceutical Co., Ltd.) and reference preparation (trade name: Bayer Aspirin®, specification: 100 mg, licensee: Bayer S.p.A.) after a single oral dose in healthy Chinese adult subjects under fasting and postprandial conditions. Secondary study objectives To study the safety of aspirin enteric-coated tablets (specification: 100 mg) and reference preparation (trade name: Bayer Aspirin®, specification: 100 mg) in healthy Chinese adult subjects.

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of aspirin enteric-coated tablets (specification: 100 mg, applicant: Heilongjiang Linbao Pharmaceutical Co., Ltd.) and reference preparation (trade name: Bayer Aspirin®, specification: 100 mg, licensee: Bayer S.p.A.) after a single oral dose in healthy Chinese adult subjects under fasting and postprandial conditions. Secondary study objectives To study the safety of aspirin enteric-coated tablets (specification: 100 mg) and reference preparation (trade name: Bayer Aspirin®, specification: 100 mg) in healthy Chinese adult subjects.